Abstract
Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-α) which is major cytokine playing pivotal role in inflammatory diseases. Efficacy and safety of infliximab was studied in numerous inflammatory skin diseases where TNF-α is involved in pathogenesis especially in psoriasis and psoriatic arthritis. This review summarizes the current data revealing the efficacy and safety of infliximab in treating various dermatoses beyond its approved indications. Results of clinical trials and case reports suggest that infliximab is a promising agent in treating inflammatory cutaneous dermatoses where conventional therapies fail to respond or have limited effect due to potential side effects.
Keywords: Infliximab, tumor necrosis factor-α, psoriasis, cutaneous dermatoses
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: The Use of Infliximab in Dermatology
Volume: 6 Issue: 3
Author(s): Melda Demirtasoglu and Emel Fetil
Affiliation:
Keywords: Infliximab, tumor necrosis factor-α, psoriasis, cutaneous dermatoses
Abstract: Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-α) which is major cytokine playing pivotal role in inflammatory diseases. Efficacy and safety of infliximab was studied in numerous inflammatory skin diseases where TNF-α is involved in pathogenesis especially in psoriasis and psoriatic arthritis. This review summarizes the current data revealing the efficacy and safety of infliximab in treating various dermatoses beyond its approved indications. Results of clinical trials and case reports suggest that infliximab is a promising agent in treating inflammatory cutaneous dermatoses where conventional therapies fail to respond or have limited effect due to potential side effects.
Export Options
About this article
Cite this article as:
Melda Demirtasoglu and Emel Fetil , The Use of Infliximab in Dermatology, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (3) . https://dx.doi.org/10.2174/187152307781368283
DOI https://dx.doi.org/10.2174/187152307781368283 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A New Phospholipase A<sub>2</sub> from Lachesis <i>muta rhombeata</i>: Purification, Biochemical and Comparative Characterization with Crotoxin B
Protein & Peptide Letters Antipsychotic Augmentation Strategies to Ameliorate Negative and Cognitive Symptoms in Schizophrenia; Implications for Future Research
Central Nervous System Agents in Medicinal Chemistry The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment - Study Results
Current Cardiology Reviews Synthesis, Anticonvulsant and Binding Interaction Study of Novel Piperamides with Bovine Serum Albumin by Fluorescence Spectroscopy
Central Nervous System Agents in Medicinal Chemistry Gemcitabine-Related Atrial Fibrillation: A Case Report and Review of the Literature
Current Drug Safety The “Parkinsonian Heart”: From Novel Vistas to Advanced Therapeutic Approaches in Parkinsons Disease
Current Medicinal Chemistry Nose to Brain Delivery of Nanoformulations for Neurotherapeutics in Parkinson’s Disease: Defining the Preclinical, Clinical and Toxicity Issues
Current Drug Delivery Pharmacological Characteristics of Parenteral IGF-I Administration
Current Pharmaceutical Biotechnology Influence of Drugs on Mild Cognitive Impairment in Parkinson’s Disease: Evidence from the PACOS Study
Current Neuropharmacology Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Development of Proteinase-Activated Receptor 1 Antagonists as Therapeutic Agents for Thrombosis, Restenosis and Inflammatory Diseases
Current Pharmaceutical Design Relevance of the Vascular Effects of Insulin in the Rationale of its Therapeutical Use
Cardiovascular & Hematological Disorders-Drug Targets New Developments in Systemic Therapy for Hepatocellular Carcinoma
Current Cancer Therapy Reviews Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Update in Glaucoma Medicinal Chemistry: Emerging Evidence for the Importance of Melatonin Analogues
Current Medicinal Chemistry New Biological Approaches in Asthma: DNA-Based Therapy
Current Medicinal Chemistry News in the Indications of Direct Oral Anticoagulants According to the American College of Chest Physicians 2016 Guidelines
Current Drug Metabolism Antibacterial Effects of Carbon Monoxide
Current Pharmaceutical Biotechnology Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design Transformation of UPLC-MS Data Overcomes Extreme Variability in Urine Concentration and Metabolite Fold Change
Current Metabolomics